Anatomical and functional imaging of metastatic pheochromocytoma

Annals of the New York Academy of Sciences

Volumn 1018, Issue , 2004, Pages 495-504

  Ilias, Ioannis ^a   Pacak, Karel ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

Computed tomography; Fluorine radioisotopes; Magnetic resonance imaging; Octreotide; Pheochromocytoma; Positron emission tomography; Radionuclide imaging

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; DIAGNOSTIC AGENT; DOPAMINE F 18; FLUORODEOXYGLUCOSE F 18; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG;

ADRENAL CORTEX CARCINOMA; ADRENAL SCINTISCANNING; CANCER DIAGNOSIS; CANCER LOCALIZATION; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DIAGNOSTIC APPROACH ROUTE; HUMAN; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; SCINTIGRAPHY; SOMATOSTATIN RECEPTOR SCINTIGRAPHY;

EID: 3242662501     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1296.061     Document Type: Conference Paper

References (103)

1. NEUMANN, H.P.H., et al. 2002. Germ-line mutations in nonsyndromic pheochromocytoma. N. Engl. J. Med. 346: 1459-1466.
2. MUNDSCHENK, J., et al. 1998. Malignant pheochromocytoma. Exp. Clin. Endocrinol. Diabetes 106: 373-376.
3. AVERBUCH, S.D., et al. 1988. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine and dacarbazine. Ann. Int. Med. 109: 267-273.
4. MORNEX, R., et al. 1992. Malignant pheochromocytoma: a series of 14 cases observed between 1966 and 1990. J. Endocrinol. Invest. 15: 643-649.
5. PROYE, C., et al. 1992. High incidence of malignant pheochromocytoma in a surgical unit. 26 cases out of 100 patients operated from 1971 to 1991. J. Endocrinol. Invest. 15: 651-663.
6. TISCHLER, A. 1998. The adrenal medulla and extra-adrenal paraganglia. In Functional Endocrine Pathology. K. Kovacs, et al., Eds.: 550-595. Blackwell Scientific. Oxford, UK.
7. SHAPIRO, B., et al. 2001. Radioisotope diagnosis and therapy of malignant pheochromocytoma. Trends Endocrinol. Metabol. 12: 469-475.
8. TRONCONE, L., et al. 1990. The diagnostic and therapeutic utility of radioiodinated metaiodobenzylguanidine (MIBG). 5 years of experience. Eur. J. Nucl. Med. 16: 325-335.
9. PACAK, K., et al. 2001. Recent advances in genetics, diagnosis, localization and treatment of pheochromocytoma. Ann. Int. Med. 134: 315-329.
10. QUINT, L.E., et al. 1987. Pheochromocytoma and paraganglioma: comparison of MR imaging with CT and I-131 MIBG scintigraphy. Radiology 165: 89-93.
11. SCHMEDTJE, J.F.J., et al. 1987. Localization of ectopic pheochromocytomas by magnetic resonance imaging. Am. J. Med. 83: 770-772.
12. MORI, S., et al. 2002. A case of metastatic extra-adrenal pheochromocytoma 12 years after surgery. Hypertens. Res. 25: 141-144.
13. BENDER, B.U., et al. 1997. Functioning thoracic paraganglioma: association with Von Hippel-Lindau syndrome. J. Clin. Endocrinol. Metab. 82: 3356-3360.
14. O'Riordain, D. S., et al. 1996. Clinical spectrum and outcome of functional extraadrenal paraganglioma. World J. Surg. 20: 916-921; discussion 922.
15. BRAEDEL, H.U., et al. 1986. Multiple extra-adrenal and thoracic pheochromocytomas. Urology 28: 95-99.
16. SHIN, M.S., et al. 1986. Thoracic pheochromocytoma: computerized tomographic characteristics. South. Med. J. 79: 244-245.
17. SHIRKHODA, A., et al. 1984. Computed tomography of juxtacardiac pheochromocytoma. J. Comput. Tomogr. 8: 207-209.
18. PEPPERCORN, P.D., et al. 1997. State-of-the-art CT and MRI of the adrenal gland. Eur. Radiol. 6: 822-836.
19. JALIL, N.D., et al. 1998. Effectiveness and limits of preoperative imaging studies for the localisation of pheochromocytomas and paragangliomas: a review of 282 cases. French Association of Surgery (AFC), and the French Association of Endocrine Surgeons (AFCE). Eur. J. Surg. 164: 23-28.
20. BOLAND, G.W., et al. 1995. Magnetic resonance imaging of the adrenal gland. Crit. Rev. Diagn. Imaging 36: 115-174.
21. MANNELLI, M., et al. 1999. Pheochromocytoma in Italy: a multicentric retrospective study. Eur. J. Endocrinol. 142: 619-624.
22. MAUREA, S., et al. 1996. Diagnostic imaging in patients with paragangliomas. Computed tomography, magnetic resonance and MIBG scintigraphy comparison. Q. J. Nucl. Med. 40: 365-371.
23. PACAK, K., et al. 2001. A "pheo" lurks: novel approaches for locating occult pheochromocytoma. J. Clin. Endocrinol. Metab. 86: 3641-3646.
24. MAUREA, S., et al. 1993. Iodine-131-metaiodobenzylguanidine scintigraphy in preoperative and postoperative evaluation of paragangliomas: comparison with CT and MRI. J. Nucl. Med. 34: 173-179.
25. BERGLUND, A.S., et al. 2001. Metaiodobenzylguanidine (MIBG) scintigraphy and computed tomography (CT) in clinical practice. Primary and secondary evaluation for localization of phaeochromocytomas. J. Intern. Med. 249: 247-251.
26. PEPLINSKI, G.R., et al. 1994. The predictive value of diagnostic tests for pheochromocytoma. Surgery 116: 1101-1110.
27. WITTELES, R.M., et al. 2000. Sensitivity of diagnostic and localization tests for pheochromocytoma in clinical practice. Arch. Intern. Med. 160: 2521-2524.
28. MAYO-SMITH, W.W., et al. 2001. State of the art adrenal imaging. Radiographics 21: 995-1012.
29. DACIE, J.E., et al. 1993. Radiology of endocrine disease. In Atlas of Endocrine Imaging. G. M. Besser, et al., Eds.: 1-78. Mosby-Wolfe. London, UK.
30. CHANG, A., et al. 1987. Adrenal gland: MRI imaging. Radiology 163: 123-128.
31. LEE, M.J., et al. 1994. State-of-the-art MR imaging of the adrenal gland. Radiographics 14: 1015-1029.
32. ARAVOT, D.J., et al. 1992. Location, localization and surgical treatment of cardiac pheochromocytoma. Am. J. Cardiol. 69: 283-285.
33. ROSS, J.H. 2000. Pheochromocytoma. Special considerations in children. Urol. Clin. North Am. 27: 393-402.
34. FRANCIS, I.R., et al. 1996. Pheochromocytoma. Radiol. Clin. North Am. 34: 1101-1112.
35. RACKLEY, R., et al. 1994. Magnetic resonance imaging of pelvic tumors in children. J. Urol. 151: 449-459.
36. PLOWMAN, P.N. 1997. Positive MIBG scanning at the time of relapse in neuroblastoma which was MIBG negative at diagnosis. Br. J. Radiol. 70: 969.
37. HUGUET, F., et al. 1996. Interaction of metaiodobenzylguanidine with cardioactive drugs: an in vitro study. Eur. J. Nucl. Med. 23: 546-549.
38. KHAFAGI, F.A., et al. 1989. Labetalol reduces iodine-131 MIBG uptake by pheochromocytoma and normal tissues. J. Nucl. Med. 30: 481-489.
39. GELFAND, M.J., et al. 1994. Iodine-123-MIBG SPECT versus planar imaging in children with neural crest tumors. J. Nucl. Med. 35: 1753-1757.
40. ROELANTS, V., et al. 1998. Iodine-131-MIBG scintigraphy in adults: interpretation revisited? J. Nucl. Med. 39: 1007-1012.
41. MOROZUMI, T., et al. 1996. Abnormal iodine-123-MIBG images in healthy volunteers. J. Nucl. Med. 37: 1686-1688.
42. FRANCESCHINI, R., et al. 1995. In vitro and in vivo studies with no-carrier added radioiodinated MIBG. Q. J. Nucl. Med. 39(Suppl. 1): 72-77.
43. ELGAZZAR, A.H., et al. 1995. I-123 MIBG scintigraphy in adults. A report of clinical experience. Clin. Nucl. Med. 20: 147-152.
44. NAKAJO, M., et al. 1983. The normal and abnormal distribution of the adrenomedullary imaging agent m-[I-131]iodobenzylguanidine (I-131 MIBG) in man: evaluation by scintigraphy. J. Nucl. Med. 24: 672-682.
45. KLINE, R.C., et al. 1981. Myocardial imaging in man with I-123 meta-iodobenzylguanidine. J. Nucl. Med. 22: 129-132.
46. LYNN, M.D., et al. 1984. Portrayal of pheochromocytoma and normal human adrenal medulla by m-[123I] iodobenzylguanidine: concise communication. J. Nucl. Med. 25: 436-440.
47. MOZLEY, P.D., et al. 1994. The efficacy of iodine-123-MIBG as a screening test for pheochromocytoma. J. Nucl. Med. 35: 1138-1144.
48. SISSON, J.C., et al. 1981. Scintigraphic localization of pheochromocytoma. N. Engl. J. Med. 305: 12-17.
49. LYNN, M.D., et al. 1985. Pheochromocytoma and the normal adrenal medulla: improved visualization with I-123 MIBG scintigraphy. Radiology 155: 789-792.
50. FUJITA, A., et al. 2000. Use of fusion images of I-131 metaiodobenzylguanidine, SPECT and magnetic resonance studies to identify a malignant pheochromocytoma. Clin. Nucl. Med. 25: 440-442.
51. SISSON, J.C., et al. 1999. Nuclear medicine imaging of pheochromocytoma and neuroblastoma. Q. J. Nucl. Med. 43: 217-223.
52. TSUCHIMOCHI, S., et al. 1997. Metastatic pulmonary pheochromocytomas: positive I-123 MIBG SPECT with negative I-131 MIBG and equivocal I-123 MIBG planar imaging. Clin. Nucl. Med. 22: 687-690.
53. SHULKIN, B.L., et al. 1986. Primary extra-adrenal pheochromocytoma: positive I-123 MIBG imaging with negative I-131 MIBG imaging. Clin. Nucl. Med. 11: 851-854.
54. NIELSEN, J.T., et al. 1996. Location of adrenal medullary pheochromocytoma by I-123 metaiodobenzylguanidine SPECT. Clin. Nucl. Med. 21: 695-699.
55. VAN DER HARST, E., et al. 2001. [(123)I]metaiodobenzylguanidine and [(111)In] octreotide uptake in benign and malignant pheochromocytomas. J. Clin. Endocrinol. Metab. 86: 685-693.
56. BRAVO, E.L. 1994. Evolving concepts in the pathophysiology, diagnosis and treatment of pheochromocytoma. Endocr. Rev. 15: 356-358.
57. MAUREA, S., et al. 2002. Diagnostic accuracy of radionuclide imaging using 131I norcholesterol or meta-iodobenzylguanidine in patients with hypersecreting or non-hypersecreting adrenal tumours. Nucl. Med. Commun. 23: 951-960.
58. BERCHTENBREITER, C., et al. 1999. Misleading diagnosis of retroperitoneal actinomycosis. Eur. Radiol. 9: 1869-1872.
59. FURUTA, N., et al. 1999. Diagnosis of pheochromocytoma using [123I]-compared with [131I]-metaiodobenzylguanidine scintigraphy. Int. J. Urol. 6: 119-124.
60. EISENHOFER, G., et al. 2000. 123I-MIBG scintigraphy of catecholamine systems: impediments to applications in clinical medicine. Eur. J. Nucl. Med. 27: 611-612.
61. KALTSAS, G., et al. 2001. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J. Clin. Endocrinol. Metab. 86: 895-902.
62. SHULKIN, B.L., et al. 1995. PET epinephrine studies of pheochromocytoma. J. Nucl. Med. 36: 229P.
63. SHULKIN, B.L., et al. 1992. PET scanning with hydroxyephedrine: an approach to the localization of pheochromocytoma. J. Nucl. Med. 33: 1125-1131.
64. SHULKIN, B.L., et al. 1999. Pheochromocytomas: imaging with 2-[fluorine-18]fluoro2-deoxy-D-glucose PET. Radiology 212: 35-41.
65. TANIGUCHI, K., et al. 2001. Metastases of predominantly dopamine-secreting phaeochromocytoma that did not accumulate meta-iodobenzylguanidine: imaging with whole body positron emission tomography using 18F-labelled deoxyglucose. Eur. J. Surg. 167: 866-870.
66. TRAMPAL, C., et al. 2002. Detection of pheochromocytoma using 11C-hydroxyephedrine-PET. Radiology 225(Suppl.): 425.
67. HOEGERLE, S., et al. 2002. Pheochromocytomas: detection with 18F-DOPA whole-body PET-initial results. Radiology 222: 507-512.
68. HOEGERLE, S., et al. 2003. 18F-DOPA positron emission tomography for the detection of glomus tumours. Eur. J. Nucl. Med. Mol. Imaging 30: 689-694.
69. HOVEVEY-SION, D., et al. 1990. Metabolic fate of injected radiolabelled dopamine and 2-fluorodopamine in rats. Neuropharmacology 29: 881-887.
70. PACAK, K., et al. 2001. 6-[18F]fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. Hypertension 38: 6-8.
71. ILIAS, I., et al. 2002. 6-[18F]-fluorodopamine positron emission tomography versus [131I]-metaiodobenzylguanidine scintigraphy in the evaluation of patients with pheochromocytoma (Abstract #P3-511). 84th Annual Meeting of the Endocrine Society: 611.
72. ILIAS, I., et al. 2003. Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. J. Clin. Endocrinol. Metab. 88: 4083-4087.
73. KRENNING, E.P., et al. 1995. Somatostatin receptor scintigraphy. In Nuclear Medicine Annual 1995. L.M. Freeman, Ed.: 242-244. Raven Press. New York, NY.
74. KRENNING, E.P., et al. 1992. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. Eur. J. Nucl. Med. 33: 652-658.
75. ARNBERG, H., et al. 1993. Distribution and elimination of the somatostatin analogue (111In-DTPA-D-Phe1)-octreotide (OctreoScan111). Acta Oncol. 32: 177-182.
76. KRAUSZ, Y., et al. 1994. Gallbladder visualization with In-111 labeled octreotide. Clin. Nucl. Med. 19: 133-135.
77. BAJC, M., et al. 1994. Distribution and dosimetry of 111In DTPA-D-Phe-octreotide in man assessed by whole body scintigraphy. Acta Radiol. 35: 53-57.
78. VANHAGEN, P.M., et al. 1994. Somatostatin analogue scintigraphy in granulomatous diseases. Eur. J. Nucl. Med. 21: 497-502.
79. OYEN, W.J., et al. 1994. Is somatostatin receptor scintigraphy suited to detection of acute infectious disease? Nucl. Med. Commun. 15: 289-293.
80. KRENNING, E.P., et al. 1993. Somatostatin receptor scintigraphy with [111In-DTPA-D-phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur. J. Nucl. Med. 20: 716-731.
81. LAURIERO, F., et al. 1995. I-131 MIBG scintigraphy of neuroectodermal tumors. Comparison between I-131 MIBG and In-DTPA-octreotide. Clin. Nucl. Med. 20: 243-249.
82. REUBI, J.C., et al. 1992. In vitro and in vivo detection of somatostatin receptors in pheochromocytomas and paragangliomas. J. Clin. Endocrinol. Metab. 74: 1082-1089.
83. LIMOURIS, G.S., et al. 1997. Comparison of In-111 pentetreotide, Tc-99m (V)DMSA and I-123 MIBG scintimaging in neural crest tumors. Anticancer Res. 17: 1589-1592.
84. KOPF, D., et al. 1997. Octreotide scintigraphy and catecholamine response to an octreotide challenge in malignant phaeochromocytoma. Clin. Endocrinol. 46: 39-44.
85. LASTORIA, S., et al. 1995. Comparison of labeled MIBG and somatostatin analogs in imaging neuroendocrine tumors. Q. J. Nucl. Med. 39: 145-149.
86. TENENBAUM, F., et al. 1995. Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma. J. Nucl. Med. 36: 1-6.
87. DE JONG, M., et al. 1998. Pre-clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Int. J. Cancer 75: 406-411.
88. DE JONG, M., et al. 1998. Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res. 58: 437-441.
89. JAMAR, F., et al. 2003. 86Y-DOTA(0)-d-Phe(1)-Tyr(3)-octreotide (SMT487) - a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur. J. Nucl. Med. Mol. Imaging 30: 510-518.
90. EPELBAUM, J., et al. 1995. Molecular and pharmacological characterization of somatostatin receptor subtypes in adrenal, extraadrenal, and malignant pheochromocytomas. J. Clin. Endocrinol. Metab. 80: 1837-1844.
91. HOUBEN, K., et al. 1994. PC12 variants deficient in norepinephrine transporter mRNA have wild type activities of several other related transporters. Neurochem. Res. 19: 743-751.
92. RAMACHANDRAN, B., et al. 1993. Differential expression of transporters for norepinephrine and glutamate in wild type, variant, and WNT1-expressing PC12 cells. J. Biol. Chem. 268: 23891-23897.
93. BEHR, T.M., et al. 1999. Diagnostic applications of radiolabeled peptides in nuclear endocrinology. Q. J. Nucl. Med. 43: 268-280.
94. EISENHOFER, G. 2003. Editorial: biochemical diagnosis of pheochromocytoma - is it time to switch to plasma-free metanephrines? J. Clin. Endocrinol. Metab. 88: 550-552.
95. CHEW, S.L., et al. 1994. Bilateral phaeochromocytomas in von Hippel-Lindau disease: diagnosis by adrenal vein sampling and catecholamine assay. Q. J. Med. 87: 49-54.
96. NEWBOULD, E.C., et al. 1991. The use of venous catheterization in the diagnosis and localization of bilateral phaeochromocytomas. Clin. Endocrinol. (Oxf.) 35: 55-59.
97. PONTREMOLI, R., et al. 1989. Multiple venous sampling for catecholamine assay in the diagnosis of malignant pheochromocytoma. J. Endocrinol. Invest. 12: 647-649.
98. COLLSTE, P., et al. 1986. The catecholamine concentration in central veins of hypertensive patients - an aid not without problems in locating phaeochromocytoma. Acta Chir. Scand. Suppl. 530: 67-71.
99. ALLISON, D.J., et al. 1983. Role of venous sampling in locating a phaeochromocytoma. Br. Med. J. (Clin. Res. Ed.) 286: 1122-1124.
100. NOBIN, A., et al. 1982. Localization of carcinoids and pheochromocytomas with vein catheterization and amine determination. Brain Res. Bull. 9: 781-797.
101. DUNNICK, N.R., et al. 1982. Localization of functional adrenal tumors by computed tomography and venous sampling. Radiology 142: 429-433.
102. BOLLI, G., et al. 1981. Simultaneous central venous and arterial blood sampling for catecholamine assay in phaeochromocytoma. Lancet 2: 526-527.
103. JONES, D.H., et al. 1979. Selective venous sampling in the diagnosis and localization of phaeochromocytoma. Clin. Endocrinol. (Oxf.) 10: 179-186.